Fig. 3 | Hypertension Research

Fig. 3

From: Efficacy and safety of esaxerenone in hypertensive patients with chronic kidney disease, with or without type 2 diabetes mellitus: a pooled analysis of five clinical studies

Fig. 3

Percentage change in UACR from baseline to Week 12 (a) and improvement rates of UACR (b) in the overall population, T2DM subgroups, and eGFRcreat subgroups (full analysis set). a Mean, error bar (95% CI); ***P < 0.001 vs baseline. b A2/A3. aRemission was defined as the transition to UACR A1 combined with a ≥ 30% reduction in UACR from baseline. A1 UACR < 30 mg/gCr, A2 UACR 30 to <300 mg/gCr, A3 UACR 300–1000 mg/gCr, CI confidence interval, eGFRcreat creatinine-based estimated glomerular filtration rate, T2DM type 2 diabetes mellitus, UACR urine albumin-to-creatinine ratio

Back to article page